TAGAMET
LOE ApproachingNDAORALTABLETPriority Review
Approved
Aug 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAGAMET is a small-molecule oral tablet approved in 1977 as an NDA by GSK. The drug's specific mechanism of action and indications are not detailed in available data, but it represents a legacy product with nearly 50 years of market presence. It is formulated as an oral tablet for systemic delivery.
LOE Approaching
With LOE approaching, the brand team is likely in transition mode, shifting focus to life-cycle extension strategies or managing declining resources as generic competition looms.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TAGAMET offers limited growth opportunity but valuable experience in navigating product lifecycle transitions, generic competition, and portfolio rationalization—skills highly transferable to other LOE products or market access roles. This is a stabilization and managed-decline opportunity rather than a launch or growth assignment.
Market Access ManagerGeneric Strategy Manager
Worked on TAGAMET at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.